
Halozyme licenses Janssen rights to Enhanze
Executive Summary
Halozyme Therapeutics Inc. licensed Janssen Biotech Inc. exclusive global rights to use its Enhanze technology to develop and commercialize therapies for up to five Janssen targets.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com